Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — Phase 2 trials
10 open options
- TRIALPHASE1 / PHASE2RECRUITING
Sense4Safety Intervention
Sense4Safety — 1 site
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
ITI-1284 · Placebo — 70 sites
- TRIALPHASE2RECRUITING
DORA and LP in Alzheimer's Disease Biomarkers
Lemborexant 10 mg · Lemborexant 20mg · Placebo — 1 site
- TRIALPHASE2ENROLLING_BY_INVITATION
A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI
Ginkgo Biloba Extract 761 — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Placebo (Study Part 1a) · ACI-24.060 at Dose A in Study Part 1a · ACI-24.060 at Dose B in Study Part 1a — 26 sites
- TRIALPHASE2RECRUITING
A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease
EX039 · Placebo — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
Glymphatic Function TMS Study
Transcranial Magnetic Stimulation
- TRIALPHASE2 / PHASE3NOT_YET_RECRUITING
To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease
Dronabinol Oral Solution · Placebo Control — 1 site
- TRIALPHASE2ENROLLING_BY_INVITATION
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk
Couples-based treatment- Patient · Couples-based treatment- Partner · Information control- Patient — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
ABBV-1758 · Placebo for ABBV-1758 · ABBV-1758 — 12 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.